Company intelligence / Profile preview

AVVA Pharmaceuticals Ltd

Limassol, Cyprus

Ownership: Private
Development stage: Other

Overview

AVVA Pharmaceuticals markets several products including Micrazym® for exocrine pancreatic insufficiency, and unique enterosorbent-based supplements for GI health and metabolic support; evidence includes clinical use and approved submissions in the EU, with ongoing registrations in new countries

Therapeutic areas: Metabolic DisordersInfectious DiseasesGastroenterologyDermatologyOther
Modalities: BiologicSmall moleculeRecombinant proteinEnzyme replacement therapyDietary supplement (non-pharmacological therapy)
Industry: Biotech

Partnerships

Collaborations with leading international research and scientific centres

Beyond the preview

Go deeper on AVVA Pharmaceuticals Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVVA Pharmaceuticals Ltd.

Explore the full profile